Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: UPTD) is a clinical-stage biopharmaceutical company focused on immunology and immune-mediated disease that accessed the public markets through a SPAC merger. The company filed an 8-K current report with the Securities and Exchange Commission on September 20, 2023, documenting a material corporate development. Estrella operates in the life sciences and biopharmaceutical sector, a space that drew concentrated SPAC activity during the early 2020s as blank-check sponsors pursued oncology, immunology, and rare-disease targets. The September 2023 filing reflects ongoing post-combination reporting obligations common to de-SPAC entities. For complete deal history, sponsor profiles, filing archives, and real-time analytics on UPTD and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.